Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Organogenesis Holdings Inc. (ORGO)

Organogenesis sets up up to $75 million at-the-market share sale program

Neutral Impact 3 of 5 financing Written later

Organogenesis entered an at-the-market sales agreement with BTIG and Citizens JMP that lets it sell Class A common stock worth up to $75 million through the agents over time. The company is not obligated to sell any shares, so any sales would depend on its instructions and would add to the number of shares outstanding.

Key points

  • Agreement dated August 6, 2026, with BTIG, LLC and Citizens JMP Securities, LLC as sales agents
  • Aggregate offering price of up to $75,000,000 under a prospectus supplement dated August 6, 2026
  • Agents receive a commission of up to 3.0% of gross sales price per share sold
  • Shares are offered under a Form S-3 shelf registration effective August 15, 2024; the company has no obligation to sell

The filing

CompanyOrganogenesis Holdings Inc. (ORGO)
Form8-K, current report
Filed with the SECAug 6, 2026, 4:45 PM ET
Accession number0001193125-26-338321

Items reported: 1.01 Material Definitive Agreement

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 06, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.